195 related articles for article (PubMed ID: 26387750)
1. 16th World Conference on Lung Cancer.
Landman A
Lancet Oncol; 2015 Oct; 16(13):1290. PubMed ID: 26387750
[No Abstract] [Full Text] [Related]
2. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA.
Wallerek S; Sørensen JB
Eur Respir Rev; 2015 Jun; 24(136):340-55. PubMed ID: 26028645
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.
Haddad FG; Kourie HR; Kattan J
Future Oncol; 2017 Feb; 13(3):201-204. PubMed ID: 27624407
[No Abstract] [Full Text] [Related]
4. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
[No Abstract] [Full Text] [Related]
5. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
Gadgeel SM
Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
[No Abstract] [Full Text] [Related]
6. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
7. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
[TBL] [Abstract][Full Text] [Related]
8. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
9. Evolving Treatment Options for Lung Cancer.
Morgensztern D; Herbst RS
Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
[No Abstract] [Full Text] [Related]
10. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.
Chuang JC; Liang Y; Wakelee HA
Hematol Oncol Clin North Am; 2017 Feb; 31(1):31-44. PubMed ID: 27912832
[TBL] [Abstract][Full Text] [Related]
12. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
Stinchcombe TE
Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
López-Brea M
Med Clin (Barc); 2016 Apr; 146 Suppl 1():1. PubMed ID: 27426240
[No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy benefits older and younger non-small cell lung cancer patients alike.
Barton MK
CA Cancer J Clin; 2012; 62(5):279-80. PubMed ID: 22847502
[No Abstract] [Full Text] [Related]
15. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer.
Van Schil PE
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):718; author reply 718-9. PubMed ID: 18329516
[No Abstract] [Full Text] [Related]
16. Gefitinib plus docetaxel in non-small-cell lung cancer.
Costa DB; Kobayashi S
Lancet; 2009 Feb; 373(9663):541; author reply 542. PubMed ID: 19217979
[No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy after pulmonary resection for lung cancer.
Mascaux C; Shepherd FA
Thorac Surg Clin; 2013 Aug; 23(3):401-10. PubMed ID: 23931022
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
19. How should "RET positive" NSCLC be treated?
Smit EF
Lung Cancer; 2017 Jun; 108():250-251. PubMed ID: 28189265
[No Abstract] [Full Text] [Related]
20. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
